

Examining and classifying reasons for missing viral loads among adults living with HIV: An extended outcome investigation and ascertainment approach in Western Kenya.

Harriet Fridah Adhiambo^{1,3}, Jayne Lewis-Kulzer², Edwin Nyagesoa¹, Sarah Gimbel³, Eliud Akama^{1,7}, Dorothy Mangale^{4,6}, Lina Montonya⁹, Ingrid Eshun-Wilson⁴, Sarah Iguna¹, Everlyne Nyandieka¹, Elizabeth Bukusi¹, Lisa Abuogi⁵, Thomas Odeny^{1,6}, Maya L. Petersen⁸, Elvin H. Geng⁴

1. Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
2. Department of Obstetrics, Gynecology, and Reproductive Services, University of California, San Francisco, CA, USA
3. Department of Child, Family and Population Health Nursing, School of Nursing, University of Washington, Seattle, WA, USA
4. Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, MO, USA
5. Department of Pediatrics, University of Colorado, USA
6. Division of Oncology, Department of Medicine, Washington University in St. Louis, MO, USA
7. Department of Global Health, University of Washington, Seattle, WA, USA
8. Divisions of Biostatistics and Epidemiology, School of Public Health, University of California Berkeley, Berkeley, U.S.A.
9. Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA.

§ Corresponding author: Harriet Fridah Adhiambo

4200 Mary Gates Memorial Drive NE
Seattle, 98105, Washington, USA
Phone number: +12065325701/+254726137703
Email: fridahadhiambo@gmail.com/ hfridah@uw.edu

E-mail addresses of authors:

JK: jayne.lewis.kulzer@gmail.com

EN: nyagesoedwin@gmail.com

SG: sgimbel@uw.edu

EA: eluakama@gmail.com

DM: d.mangale@wustl.edu

LM: lmontoya@unc.edu

IW: wilson.ingrid@gmail.com

SI: sarah.iguna@gmail.com

EN: everlynenyandieka@gmail.com

EB: ebukusi@rctp.or.ke

LA: Lisa.Abuogi@childrenscolorado.org

TA: odeny@wustl.edu

MP: mayaliv@berkeley.edu

EG: elvin.geng@wustl.edu

Keywords: Viral load, monitoring, HIV, Africa, and treatment

Word count:

Abstract: 300/300

Main text: 3490

1 **Abstract**

2 **Introduction:** Gaps in HIV RNA monitoring persist globally impeding the ability to determine
3 clinical progress and outcomes. This study systematically evaluated provider (e.g., guideline non-
4 adherence), system (e.g., laboratory error) and patient-based (e.g., refusal) drivers of missed viral
5 load (VL) monitoring measurements among adults living with HIV in Kenya.

6 **Methods:** Adults aged 18-65 years were followed across five health facilities in Kenya as part of
7 a clinical trial (NCT#02338739) where HIV RNA monitoring was done routinely. Instances of
8 missed VL despite being indicated per Kenyan guidelines were identified. An algorithm for
9 assessing root causes of missing HIV RNA was developed and generalized linear models estimated
10 the risk ratios (RR) for patient-level characteristics associated with missed viral load.

11

12 **Results:** Among 1,754 patients (66% female), the prevalence of missed viral load in year one and
13 two was 24.4% and 29.4%, respectively. Drivers for missed viral load measurements included loss
14 to follow up (51.5% in year one and 57.8% in year two), clinician non-adherence with guidelines
15 (36.7% in year one and 32.2% in year two), unknown (10.3% in year one and 8.6% in year two),
16 and requested but not collected (1.5% in year one and 1.3% in year two). Patients aged < 24 years
17 (RR 2.27, 95% CI: 1.66-3.12), those with higher socioeconomic status (RR 1.47, 95% CI: 1.03-
18 1.91), receiving HIV treatment at a rural clinic (RR 1.22, 95% CI: 1.02-1.46) and with advanced
19 HIV disease (RR 2.39, 95% CI: 1.52-3.73) were more likely to miss VL monitoring.

20 **Conclusions:** Missed routine viral load monitoring remains high, primarily due to loss to follow-
21 up, and may substantially alter suppression estimates. Sustainable approaches to keep people living
22 with HIV engaged in care, alongside strengthening providers' clinical practices and alignment with
23 national guidelines, are necessary for optimizing viral monitoring and accurately assessing viral
24 suppression within public health systems.

25

26 **Introduction**

27 The HIV response has greatly reduced mortality globally and in sub-Saharan Africa, including
28 Kenya [1]. The introduction of routine viral load monitoring for people on treatment for HIV in
29 Kenya was anticipated to be a gamechanger in 2013 [2]. Universal access to viral load allows
30 clinicians to monitor patient health more effectively - detecting treatment failure earlier than
31 laboratory measures such as CD4 cell counts or clinical symptoms such as opportunistic
32 infections, resulting in improved management and decreased morbidity and mortality [3].
33 Previously viral load measurements were reserved for complex patient cases or suspected viral
34 cases among extremely ill patients, with routine care measures relying on clinical or
35 immunological indicators [3], [4].

36 Despite the importance of routine viral load monitoring, gaps in HIV RNA monitoring persist,
37 impeding clinician ability to determine and shape patients' clinical progress and outcomes.
38 Existing data suggest that missed opportunities for viral load monitoring stem from a variety of
39 complex and multilevel health system barriers including reagent stock outs, staff shortages, poor
40 equipment maintenance and delayed clinical review and action on viral load results all of which
41 impede progress toward epidemic control [5], [6]. An inefficient viral load monitoring system
42 not only compromises a clinician's ability to accurately detect treatment failure, but also delays
43 provision of timely treatment interventions to patients experiencing virologic failure, leading to
44 increased morbidity (including drug resistance), risk of HIV transmission as well as risk of
45 mortality [7], [8]. Additionally, there is a risk of missing broader trends and accurately
46 measuring viral suppression within the population.

47 Research has focused on associated factors of virologic failure, viral load uptake and monitoring,
48 and cost effectiveness of routine viral load monitoring [9], [10], [11], [12], [13]. The WHO

49 recommends routine viral load testing at 6 and 12 months post ART initiation and every 12
50 months thereafter [14]. In Kenya, although routine viral load monitoring has improved since its
51 introduction, patient follow up and data management systems at the facility level are known
52 barriers to the viral load monitoring process [15]. However, there is limited data examining the
53 degree of drivers of missing viral load among people with HIV [8]. To better discern issues
54 contributing to these gaps, we developed an algorithm to assess the root causes of missing HIV
55 RNA among adult patients with HIV on antiretroviral therapy (ART) and examined patient
56 characteristics and processes associated with timely viral load monitoring.

57

58

59 **Methods**

60 **Study Design**

61 This cohort study was nested within a larger sequential multiple assignment trial (SMART),
62 AdaPT-R (NCT#02338739) study in Kenya. In the larger trial, HIV RNA monitoring during the
63 study was conducted entirely through routine service delivery processes at public health facilities
64 (i.e., the research staff did not ensure monitoring) and were thus representative of wider health
65 systems practice.

66 **Study setting**

67 The AdaPT-R study was conducted in the Nyanza region of western Kenya from September
68 2014 to December 2019 at five health facilities, including four government hospitals and one
69 faith-based health center [16]. Three sites were in urban Kisumu County: Lumumba Sub County
70 Hospital, Ahero Sub County Hospital, and Pandipieri Health Center. The other two sites were in

71 more rural areas including Migori County: Rongo Sub County Hospital and Migori County
72 Referral Hospital. Both counties have a high HIV prevalence, 19.3% in Kisumu and 13.3% in
73 Migori, compared to the national prevalence of 4.9% [17], [18], [19].

74 **Study population**

75 The study population included people living with HIV (PWH), ≥ 18 years of age who had
76 initiated ART within 90 days of study enrollment, planned to remain in the Nyanza region for the
77 duration of the study, had cell phone access and ability to read or be read short messages (SMS)
78 messages, and were willing to be contacted by a clinic worker upon missing a clinic
79 appointment. Participants were recruited and enrolled from HIV clinics at the five health
80 facilities. In this sub-study, we included all AdaPT-R participants. Participants who missed viral
81 load measurements during their 1st and 2nd year in the study. AdaPT-R participants that had died
82 or withdrew from the study before the extended outcome investigation were excluded.

83 **Ethical approvals**

84 The institutional review boards of the University of California, San Francisco (UCSF IRB No.
85 13–12810) and the Kenya Medical Research Institute (KEMRI SSC No 2838) in Kenya
86 approved this study. All participants provided informed consent to participate.

87 **Measurement of patient characteristics associated with missed viral load**

88 The sociodemographic, socioeconomic, and clinical characteristics of participants were captured
89 at study enrollment from March 2015-October 2018. Data was entered in Open Data Kit (ODK)
90 and the patient clinical characteristics, collected as part of routine patient care, were entered into
91 an electronic medical record system maintained by the Family AIDs Care and Education

92 Program (FACES). The data from both sources were then synchronized daily to the study
93 database. For this sub-study, sociodemographic variables of interest were abstracted from the
94 study database at study enrollment and included age, gender, educational status, marital status
95 and socioeconomic variables including household size, and occupation, as well as clinical
96 characteristics including WHO stage, baseline CD4, study site, and viral load history.

97 **Procedures and Measurement**

98 This study and the participating health facilities followed National ART Guidelines for viral load
99 monitoring which recommend that viral load testing be conducted 6- and 12-months post ART
100 initiation and annually thereafter for adults with viral suppression (defined as <1000 copies per
101 mL during the study period).[20] Patients without viral suppression undergo adherence
102 counseling and repeat viral load is recommended after three months of good adherence. As part
103 of routine care, patient viral load samples are taken at the facility and then sent to centralized
104 laboratories including the Kenya Medical Research Institute -Center for Disease Control
105 (KEMRI-CDC) laboratories at Kisian in Kisumu and the Academic Model Providing Access to
106 Healthcare laboratories (AMPATH) in Eldoret for processing. As part of national standards, all
107 results are uploaded and stored on the National STI and AIDs Control Program (NASCOP)
108 website by the laboratories and results are returned to the health facility. Results are then updated
109 in patient medical records, ideally both in paper files and in the electronic medical system
110 (EMR). Patients are then informed of results during their next clinic visit if they are suppressed
111 and notified to return to the clinic for their results if they are not suppressed. To examine viral
112 load missingness and drivers of missingness in this sub-study, a two-step process was employed.

113 **Step 1:** Outcome ascertainment (confirming missingness)

114 The study identified patients who did not have a HIV RNA measurement documented in the
115 study database between 9-15 months post ART initiation and 21-27 months post ART initiation
116 (i.e., windows in which guideline recommended 12- and 24-month HIV RNA measurements are
117 to be obtained). Research assistants then explored clinic records by checking the EMR, the
118 patient paper medical records, and the NASCOP website for any viral load within the established
119 window period. If a viral load measurement was found during the window period, the result and
120 date were documented on the report and entered in the study database; the participant was then
121 removed from the missing viral load report. Those who remained on the missing viral report
122 moved to Step 2.

123 **Step 2:** Ascertainment of reason for missing viral load

124 This involved investigating the missing viral load measurement further through an “extended
125 investigation” and, if the HIV RNA was confirmed missing, classifying the reason for
126 missingness. This occurred during the same month as step 1 then continued monthly until all
127 reviews were completed for a single participant. Reasons for missingness were classified based
128 on reviews of patient records and consultations with facility clinicians through a process which
129 encompassed research assistants conducting a series of review in the following order: 1. In-depth
130 review of the entire patient file; 2. Repeat review of the EMR; 3. Examination of laboratory
131 records and logs. 4. Repeat review of the NASCOP website; 5. Review study records (e.g.,
132 tracking logs); 6. Consultation with research assistants for participants in their case load; and 7.
133 Review study lost to follow up records. Viral loads found through this extended investigation
134 were documented in the study database and the participant was removed from missingness
135 report. Classification of missingness was further informed by patient status during the window
136 period of interest and included death, official or self-transferred to another facility, and non-

137 transfer (Appendix 1). If a non-transfer, the patient file was reviewed to see if the patient had a
138 clinic visit during the viral load window period of interest and if they did, clinical factors were
139 examined to determine if it was a: 1. Clinician decision and 2. Viral load ordered, but sample not
140 collected. The patient status outcomes and clinical factor outcomes were entered in the study
141 database.

142 **Analysis**

143 Missed viral load was defined as no viral load results within 9-15 months (First year of study)
144 and 21-27months of ART initiation (Second year of study). Descriptive statistics were used to
145 determine the prevalence of missed viral load and reasons for missing viral load measurements.
146 In our analysis we conducted complete case analyses by excluding missing values.
147 Socioeconomic status (SES) indices were generated using multiple correspondence analysis
148 (MCA) using the following variables: occupation of household head, primary source of drinking
149 water, type of cooking fuel, ownership of household assets and ownership of livestock. The
150 households were categorized into five socioeconomic quintiles classified as poorest, poorer,
151 middle, richer and richest [21], [22]. A generalized linear model, using a Poisson distribution
152 with a log-link function, was used to estimate adjusted risk ratios (RR) to determine the patient-
153 level characteristics associated with missed viral load in year one and year two [23]. We
154 identified covariates from the literature review and used them in the bivariate and multivariate
155 analysis [24], [25], [26].

156

157 **Results**

158 A total of 1815 participants were enrolled to the Adapt-R study. **Table 1** below describes
159 participant characteristics at one and two years of follow-up. Sixty-six percent of study
160 participants were females and over half (54.8%) were from urban clinics. No differences in
161 background characteristics in the first and second year.

Table 1: Background Characteristics

	Overall for year 1 (N=1754) n (%)	Overall for year 2 (N=1709) n (%)
Gender		
Female	1165(66.4)	1141(66.8)
Male	589(33.6)	568(33.2)
Age group (Years)		
<24	280(15.9)	208(12.1)
24-34	816(46.5)	794(46.4)
35-44	402(22.9)	431(25.2)
>44	256(14.6)	276(16.2)
Household Size		
1-2	393(22.4)	386(22.6)
3-4	663(37.9)	648(38.0)
>5	692(39.5)	669(39.2)
Social Economic Status		
Poorest	351(20.0)	338(19.7)
Poorer	351(20.0)	341(19.9)
Middle	351(20.0)	344(20.1)
Richer	351(20.0)	344(20.1)

Clinic	Richest	350(19.9)	342(20.0)
	Urban	956(54.5)	937(54.8)
	Rural	798(45.5)	772(45.2)
WHO Stage	1	1,053(61.3)	1032(61.5)
	2	508(29.6)	497(29.6)
	3	147(8.6)	138(8.2)
	4	10(0.5)	9(0.5)

162

Table 2: Cumulative incidence of viral load monitoring among ADAPT-R study participants

Viral load post ART initiation	n (%)
Year 1 (N=1754)	1269(72.3)
Year 1 Delay* (N=1754)	274(15.6)
Year 2 (N=1709)	1179(68.9)
Year 2 Delay* (N=1709)	121(7.1)


**Delay indicates participants who missed a viral load measure during the window period but later received the viral load test. The drop off in N was due to deaths, study withdrawal or loss to follow up.*

163

164 Prevalence of missed viral load

165 Prevalence of missing viral load at year one was (428/1754) 24.4% whereas the prevalence of
166 missing viral load at year two was (502/1709) 29.4%. The cumulative incidence of viral load
167 monitoring was 72.3% and 68.9% in year one and two respectively (Table 2) with an additional
168 15.6% at year one and 7.1% at year two having delayed viral loads measured.

169 Figure 1. Reasons for Missing Viral Load Measurements at Year 1




170

171 At year one, the most common reason for missed viral load was due to missing all appointments,
172 and thus being lost to follow up, during the VL window period (N= 209 (51.5%). However, of
173 the 406 patients who were alive and missed VL monitoring measurements, 149 (36.7%) missed
174 viral load monitoring as a result of mis-interpretation of routine viral load monitoring guidelines
175 with clinicians ordering VL 12 months from the last VL done as opposed to 12 months from
176 ART initiation., An additional 42 (10.3%) patients had unknown reason for missed VL and 6

177 (1.5%) patients had viral load ordered but there was no evidence the samples were collected.
 178 **(Figure 1)**

179

180 **Figure 1. Reasons for Missing Viral Load Measurements at Year 2**



181

182 Similarly, at year two, of the 475 patients who were alive and did not have a VL measured, the
 183 most common reason was missed appointments (N=275 (57.8%)), with 153 (32.2%) patients
 184 missing their viral load measurements because of misinterpretation of the guideline timing, 41
 185 (8.6%) with no known documented reason, and 6 (1.3%) had their viral loads requested by the
 186 clinicians but there was no evidence the samples were ever collected.**(Figure 2)**

187

Table 3. Multivariate analysis of patient characteristics associated with missed viral load in Year1

Total N =	Missed VL	Have VL	Unadjusted	Adjusted RR	P-value
--------------	-----------	---------	------------	-------------	---------

	1754(%)	N=485(%)	N=1269(%)	RR (95%CI)	(95%CI)	
Gender						
Female	1165(66.4)	321(66.2)	844(66.5)	0.98(0.84-1.16)	0.86(0.73-1.01)	0.075
Male	589(33.6)	164(33.8)	425(33.5)	Ref		
Age group (Years)						
<24	280(15.9)	109(22.4)	171(13.4)	2.21(1.63-2.99)*	2.27(1.663.12)*	<0.001
24-34	816(46.5)	239(49.2)	577(45.4)	1.66(1.25-2.21)*	1.70(1.272.28)*	<0.001
35-44	402(22.9)	92(18.9)	310(24.4)	1.30(0.94-1.79)	1.26 (0.91-1.75)	0.155
>44	256(14.6)	45(9.2)	211(16.6)	Ref		
Household Size						
1-2	393(22.4)	114(23.6)	279(22.0)	Ref		
3-4	663(37.9)	186(38.5)	477(37.6)	0.96(0.79-1.17)	0.99(0.81-1.20)	0.933
>5	692(39.5)	182(37.7)	510(40.2)	0.90(0.74-1.10)	1.03(0.84-1.27)	0.719
SES						
Poorest	351(20.0)	80(16.4)	271(21.3)	Ref		
Poorer	351(20.0)	93(19.1)	258(20.3)	1.16(0.89-1.50)	1.16(0.89-1.52)	0.257
Middle	351(20.0)	108(22.2)	115(23.7)	1.35(1.05-1.73)*	1.30(1.01-1.69)*	0.047
Richer	351(20.0)	115(23.7)	236(18.6)	1.43(1.12-1.83)*	1.51(1.14-1.99)*	0.003
Richest	350(19.9)	89(18.3)	261(20.5)	1.11(0.85-1.45)	1.19(0.87-1.63)	0.263

Clinic

Urban	956(54.5)	235(48.4)	563(44.3)	Ref		
Rural	798(45.5)	250(51.5)	706(55.6)	1.12(0.96-1.31)	1.22(1.02-1.46)*	0.029

WHO Stage

1	1053(61.3)	285(60.6)	768(61.5)	Ref		
2	508(29.6)	137(29.1)	371(29.7)	0.99(0.83-1.18)	1.09(0.92-1.30)	0.306
3	147(8.6)	46(9.7)	101(8.0)	1.15(0.89-1.14)	1.22(0.94-1.59)	0.117
4	10(0.5)	2(0.4)	8(0.6)	0.73(0.21-2.56)	0.76(0.21-2.72)	0.681

*significant

RR- risk ratio

SES-Social Economic Status

188

Table 4. Multivariate analysis of patient characteristics associated with missed viral load in year 2

	Total N = 1709(%)	Missed VL N=520(%)	Have VL N=1189(%)	Unadjusted RR (95%CI)	Adjusted RR (95%CI)	P-value
Gender						
Female	1141(66.8)	343(65.9)	798(67.1)	0.98(0.84-1.16)	0.86(0.73-1.01)	0.059
Male	568(33.2)	177(34.1)	391(32.8)	Ref		
Age group (Years)						
<24	208(12.1)	91(17.5)	117(9.8)	1.85(1.42-2.41)*	1.69(1.28-1.22)*	<0.001*
24-34	794(46.4)	253(48.6)	541(45.5)	1.35(1.06-1.71)*	1.27(0.99-1.63)	0.059
35-44	431(25.2)	111(21.3)	320(26.9)	1.09(0.83-1.42)	1.01(0.75-1.33)	0.997

>44	276(16.1)	65(12.5)	211(17.7)	Ref		
Household Size						
1-2	386(22.6)	136(26.3)	250(21.0)	Ref		
3-4	648(38.0)	207(40.1)	441(37.1)	0.90(0.76-1.08)	0.92(0.77-1.10)	0.381
>5	669(39.2)	173(33.5)	496(41.7)	0.73(0.60-0.88)	0.82(0.68-1.01)	0.061
SES						
Poorest	338(19.7)	84(16.1)	254(21.3)	Ref		
Poorer	341(19.9)	95(18.2)	246(20.6)	1.12(0.87-1.44)	1.08(0.80-1.40)	0.566
Middle	344(20.1)	101(19.4)	243(20.4)	1.18(0.92-1.51)	1.11(0.85-1.44)	0.429
Richer	344(20.1)	131(25.1)	213(17.9)	1.53(1.21-1.92)*	1.47(1.03-1.91)*	0.004*
Richest	342(20.0)	109(20.9)	233(19.6)	1.28(1.01-1.63)*	1.17(0.87-1.57)	0.287
Clinic						
Urban	937(54.8)	288(55.3)	649(54.5)	Ref		
Rural	772(45.2)	232(44.6)	540(45.4)	0.97(0.84-1.12)	1.10(0.92-1.57)	0.264
WHO Stage						
1	1032(61.5)	325(64.1)	707(60.4)	Ref		
2	497(29.6)	131(25.8)	366(31.3)	0.83(0.70-0.99)	0.88(0.74-1.05)	0.185
3	138(8.2)	45(8.8)	93(7.9)	1.03(0.80-1.33)	1.06(0.82-1.37)	0.649
4	9(0.5)	6(1.2)	3(0.3)	2.11(1.32-3.38) *	2.39(1.52-3.73) *	<0.001*

*significant

SES-Social Economic Status

189 Multivariate analysis of patient characteristics associated with missed viral load in year 1 and
190 year 2 reveals that younger participants age < 24 years (Year 1 aRR=2.27;95%CI 1.66-3.12;
191 p<0.001, Year 2 aRR= 1.69; 95%CI 1.28-1.22 p<0.001) had a higher risk of missed viral load as
192 compared to those whose age group is > 44 years. Participants whose Socio-Economic Status
193 (SES) were richer (Year 1 aRR=1.51;95%CI 1.14-1.99; p=0.003 and Year 2 aRR= 1.47 95%CI
194 (1.03-1.91, p=0.004) also had a higher risk of missed viral load as compared to those with
195 poorest SES. Additionally, participants from rural clinics in year 1 (aRR=1.22;95%CI 1.02-1.46;
196 p=0.029) had a higher risk of missed viral load as compared to those whose clinics were urban
197 (**Table 3 and Table 4**), whereas participants in Year 2 categorized as WHO stage 4 had a higher
198 risk of missed viral load compared to participants in WHO stage 1(aRR=2.39; 95%CI 1.52-3.73,
199 P<0.001). Stratified analysis comparing patient characteristics by rural vs urban did not change
200 associations with missed viral load in year 1 and 2 respectively.

201 Additional findings from the research team's perspective revealed that some clinicians
202 deliberately avoiding conducting viral load measurements from patients suspected to be viremic.
203 These were patients who reported missing doses of ART or had tendencies of missing their clinic
204 appointments. However, this practice was not documented in the patients file but reported by
205 some clinicians when contacted by the research staff during the extended outcome investigation.

206 **Discussion**

207 An effective viral load monitoring system is critical to early intervention and prevention of poor
208 health outcomes as a result of viremia for PWH. Poor coverage of clinical monitoring systems
209 impedes the ability of HIV programs and country health officials to determine population
210 outcomes. This study showed that about a third of study participants eligible and due for viral load
211 measurement after initiating treatment were missing their viral load at key monitoring timepoints.

212 These findings are similar a study conducted in South Africa that showed 32% and 26% of the
213 participants did not get a viral load test in the first and second years after ART start [27], [28].
214 Although WHO recommendation for viral testing led to rapid scale up of viral load monitoring
215 among PWH on treatment, these findings suggest health system issues resulting in less-than-ideal
216 viral load monitoring. Over the past five years there has been considerable improvement in viral
217 load monitoring; however, gaps in viral load monitoring of patients still persist [30]. HIV treatment
218 success is defined by early diagnosis, prompt ART initiation and viral suppression [31]. With over
219 a third of the patients missing routine VL measurements, VL monitoring is incomplete, leading to
220 undetected cases of failure, resistance, and risk of HIV transmission; subsequently undermining
221 attainment of the UNAIDs 95-95-95 goals [10]. Thus, it is essential to understand why viral load
222 monitoring is incomplete so the gaps can be addressed.

223 This study showed that patient engagement in care plays an important role in the missingness of
224 viral loads, with approximately 54.7% of patients missing their viral load because they were lost
225 to follow up. Patients who were lost to follow up had unknown whereabouts and potentially
226 could be out of HIV care, may have self-transferred to another clinic without documentation, or
227 died without the clinic's knowledge. Attrition in care engagement leads to underestimation or
228 overestimation of the progress of HIV care and treatment programs. Participant tracing, social
229 support, and reminder systems may improve retention and lead to more complete viral load
230 monitoring outcomes [16]. Some studies using SMS to enhance HIV care and treatment cascade,
231 by engaging both patients and clinicians for reminders about testing, viral load result
232 notification, and patient tracing have proven to be effective [32], [33]. Manpower needs are
233 critical in HIV clinics to follow up patients out of care for care engagement and viral load
234 monitoring [34].

235 Our findings also revealed that patient’s missed viral load monitoring due to clinical factors. At
236 both 12 and 24 months after ART initiation, over one third of the patients who were in care
237 missed viral load monitoring measurements because of misinterpretation of the guidelines and
238 failure to ensure patients sent for viral load tests in the laboratory followed through. Although the
239 guidelines indicate viral load monitoring for adults is done at 6, 12, and 24 months after ART
240 initiation [35], clinicians commonly interpreted the guidelines as recommending viral loads at 6
241 months, then 12 months from the last viral load done (e.g. 18 months) and 30 months. The study
242 team struggled to get concurrence on our interpretation of the guidelines with some clinical and
243 program teams during the study period. This demonstrated a gap in understanding of the
244 guidelines translating to incomplete VL monitoring as required. Providers need to know when
245 treatment isn’t working, and timely viral load measurement provides that knowledge. This is
246 especially important during the first year on antiretroviral therapy (ART), as most treatment
247 failures occur during this period [36], [37], which is why the 6 and 12-month viral load tests are
248 recommended. It is also motivating for patients to know if their treatment is working to stay on
249 track or to figure out what action is needed. Viral suppression allows patients living with HIV to
250 stay health and to prevent onward HIV transmission. To mitigate these clinical challenges,
251 capacity building through training, strong clinical guidance and support supervision by program
252 managers are pivotal components of compliant guideline implementation [38], [39].

253 We observed that patients living with HIV with a WHO clinical stage 4, those in rural health
254 facilities, younger patients <24 years and those with a higher SES had a higher risk of missing
255 viral load tests. The advance clinical stage results are consistent with findings from a study
256 conducted in Myanmar that examined viral load testing uptake and implementation challenges;
257 the study demonstrated that patients with WHO clinic stage 4 had significantly higher rates of

258 not being tested for viral load [40]. Perhaps, tracing these patients in addition to those who are
259 loss to follow up can reduce the missed opportunity for viral load monitoring and investigating
260 more on patients with advanced HIV. Younger patients <24 years were more likely to miss viral
261 load measurements compared to those above 44 years. This was similar to findings from a study
262 conducted in Gomba, Uganda looking at non uptake of VL that reported people below 25 years
263 of age to be less likely to have a VL test [27]. Perhaps younger people are more mobile and
264 likely to be out of care hence missing out on routine viral load monitoring [41]. Patients
265 receiving HIV care and treatment in more rural health facilities such as Migori and Rongo
266 counties had a higher risk of missing viral load monitoring measurements compared to those in
267 urban facilities in Kisumu County. It has been shown that the testing rates in urban and
268 developed health facilities are higher compared to rural areas [42]. These discrepancies are due
269 to lack of testing equipment, poor access to health facilities, differences in the level of training of
270 the health care workers, and weak transport and storage systems [26], [42], [43]. Low
271 socioeconomic status has extensively been demonstrated to be associated with poor health
272 outcomes such as increased morbidity and mortality, lack of adherence to clinic attendance and
273 treatment [44], [45], [46], [47]. Contrary to these finding, our study showed that those who were
274 richer/socioeconomically advantaged were at a higher risk of missing viral load monitoring
275 measurements compared to the poorest. A possible explanation could be that they felt healthy
276 and disregarded the viral load tests or they could possibly be among those who were disengaged
277 in care at the time for viral load test or self-transferred to other facilities. Further investigations
278 are needed to obtain an in depth understanding of this finding.

279 **Strengths and limitations**

280 The extended outcome investigation approach is a good way to complete viral load outcomes at
281 various clinics. Often, we do not routinely explore reasons for missed viral load measurements.
282 This study not only examined the occurrence of missed viral loads but also explored underlying
283 causes. The study obtained routinely collected data from the facilities thus demonstrating real
284 world practice. The study sites' location provided a comparison of the urban and rural facilities in
285 Western Kenya, yet the finding may not be generalizable to other regions of Kenya. We were not
286 able to establish other factors that could have led to missed viral load- like reagent stock outs,
287 machine breakdown and impact of health care worker strikes on HIV care and treatment.
288 Conducting qualitative interviews and facility assessments would have complemented our results.
289 We had information on participants who had transferred to other health facilities but had limited
290 outcome data. Strengthening facility linkage across clinics would ensure continuity of care and
291 documentation of patient outcomes. Additionally, clinicians avoided viral load measurements
292 among patients suspected to be viremic. Given that this practice is not documented, we did not
293 obtain data on the estimates of patients who did not receive VL monitoring due to suspected
294 viremia by the clinicians.

295

296

297 **Conclusions**

298 Missed routine viral load monitoring among newly initiating PWH in Kenya remains high. Loss
299 to follow-up is the major source of missing information and could alter overall suppression
300 estimates substantially. Sustainable approaches to keep people living with HIV engaged and
301 strengthening providers alignment with national guidelines can help public health systems make
302 the most of viral load monitoring technology among patients living with HIV.

303 **Competing interests**

304 All authors report no conflict of interest.

305

306 **Authors' contributions**

307 HAF and EG conceptualized and designed the study. HAF, SI, EN, and JK were responsible for
308 data collection. EN performed data analysis and interpretation. HAF drafted the initial manuscript.

309 All authors critically reviewed the manuscript, contributed to revisions, and approved the final
310 version for submission.

311

312 **Acknowledgements**

313 We would like to thank all the ADAPT-1 study staff for their invaluable contributions to this
314 manuscript. Special thanks to the Research Assistants who were key in the investigation process
315 and all the study participants.

316

317 **Data Availability Statement**

318 The data that support the findings of this study are available on request from the corresponding
319 author. The data are not publicly available due to privacy or ethical restrictions.

320

321

322

323

324

325

326 **Appendix A: Extended outcome investigation form (EOIC).**

Appendix B28_ADAPT4A Extended Outcome Investigation and Classification form		
Study ID: <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> Date: <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>		
Unique Patient Number: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> VL investigation: <input type="checkbox"/> Month 6 post rerandomization <input type="checkbox"/> Year 1 <input checked="" type="checkbox"/> Year 2		
Anniversary Date: <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	Viral Load (VL) window: Start date: <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	
Date of Enrolment: <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	End date: <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	
Section A: Patient status during VL window		
Died before or during VL window?	<input type="checkbox"/> No ↓	<input type="checkbox"/> Yes: Death date <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> Fill ADAPT OA form and discontinuation form Move to Section D
Withdrew from ADAPT study before or during VL window?	<input type="checkbox"/> No ↓	<input type="checkbox"/> Yes: Withdrawal date <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> Fill ADAPT withdrawal form Move to Section D
Transferred out of ADAPT clinics before or during the VL window?	<input type="checkbox"/> No Move to Section C	<input checked="" type="checkbox"/> Yes: Transfer-out date <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> DD- <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> Fill discontinuation form, if needed Move to Section B
Section B: Transfer-out patient		
Type of transfer out: <input type="checkbox"/> Self Transfer <input type="checkbox"/> Official Transfer		
Can you confirm the patient attended a new clinic?	<input type="checkbox"/> No →	<input type="checkbox"/> Staff is certain patient is/was not in care during window <input type="checkbox"/> Staff has no knowledge of patient whereabouts Move to Section D
	<input type="checkbox"/> Yes ↓ Attempt to get VL data. If able, enter data in ODK. <u>STOP HERE</u> If unable to get VL information within the window period →	<input type="checkbox"/> New clinic refused to provide any additional information on the patient <input type="checkbox"/> New clinic has not taken VL because patient not on treatment, or recently started treatment, or patient enrolled as new at the clinic <input type="checkbox"/> New clinic has some evidence patient is in care but cannot obtain VL <input type="checkbox"/> No VL result available, reason unknown <input type="checkbox"/> New clinic certain patient is/was not in care in the VL window <input type="checkbox"/> New clinic obtained VL outside window period(VL date and result) Move to Section D
Section C: Non-transfer patient		
Did patient have a visit to ADAPT clinic in the VL window?	<input type="checkbox"/> No →	<input type="checkbox"/> Staff is certain patient is/was not in care during window If patient transferred filled Section B. If patient died, fill Section A. <input type="checkbox"/> Staff have some evidence patient is in care, but cannot obtain VL <input type="checkbox"/> Staff has no knowledge of patient whereabouts Move to Section D
	<input type="checkbox"/> Yes →	<input type="checkbox"/> Clinician refused to order because patient not on treatment or recently restarted <input type="checkbox"/> Clinician refused to order because ADAPT window did not match time points for clinical VL <input type="checkbox"/> Clinician did not order, reason unknown <input type="checkbox"/> Clinician ordered, but no evidence VL ever collected <input type="checkbox"/> No VL ordered, but known to staff to be off medication completely Move to Section D
Section D: Data sources(select multiple choices)		
Data sources	<input type="checkbox"/> Clinic patient file <input type="checkbox"/> Clinic Lab Log <input type="checkbox"/> New clinic staff (transfer patients only) <input type="checkbox"/> Clinic staff (e.g. SSD, clinical team, Lab technicians) <input type="checkbox"/> A4A records (e.g. patient files, logs, diaries) <input type="checkbox"/> IP-Nav knowledge <input type="checkbox"/> E-navigator knowledge <input type="checkbox"/> A4A LTFU investigator <input type="checkbox"/> CM team <input type="checkbox"/> VL/ gid website	

327

328

329 **References**

- 330 [1] “Global HIV & AIDS statistics — 2019 fact sheet.” Accessed: Feb. 20, 2020. [Online].
331 Available: <https://www.unaids.org/en/resources/fact-sheet>
- 332 [2] J. Kadima *et al.*, “Adoption of routine virologic testing and predictors of virologic failure
333 among HIV-infected children on antiretroviral treatment in western Kenya,” *PLoS One*, vol.
334 13, no. 11, Nov. 2018, doi: 10.1371/journal.pone.0200242.
- 335 [3] C. Laxmeshwar *et al.*, “Routine viral load monitoring and enhanced adherence counselling
336 at a public ART centre in Mumbai, India,” *PLoS One*, vol. 15, no. 5, p. e0232576, May
337 2020, doi: 10.1371/journal.pone.0232576.
- 338 [4] M. S. Saag *et al.*, “HIV viral load markers in clinical practice,” *Nat Med*, vol. 2, no. 6, pp.
339 625–629, Jun. 1996, doi: 10.1038/nm0696-625.
- 340 [5] S.-P. Eholié, F. E. Aoussi, I. S. Ouattara, E. Bissagnéné, and X. Anglaret, “HIV treatment
341 and care in resource-constrained environments: challenges for the next decade,” *J Int AIDS
342 Soc*, vol. 15, no. 2, p. 17334, Aug. 2012, doi: 10.7448/IAS.15.2.17334.
- 343 [6] S. Lecher, “Progress with Scale-Up of HIV Viral Load Monitoring — Seven Sub-Saharan
344 African Countries, January 2015–June 2016,” *MMWR Morb Mortal Wkly Rep*, vol. 65,
345 2016, doi: 10.15585/mmwr.mm6547a2.
- 346 [7] N. S. Mark *et al.*, “Evaluation of the Management of Patients with Detectable Viral Load
347 after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in
348 Uganda,” *AIDS Res Treat*, vol. 2019, p. 9271450, Dec. 2019, doi: 10.1155/2019/9271450.
- 349 [8] P. D. Ehrenkranz *et al.*, “The missed potential of CD4 and viral load testing to improve
350 clinical outcomes for people living with HIV in lower-resource settings,” *PLOS Medicine*,
351 vol. 16, no. 5, p. e1002820, May 2019, doi: 10.1371/journal.pmed.1002820.
- 352 [9] R. V. Barnabas, P. Revill, N. Tan, and A. Phillips, “Cost-effectiveness of routine viral load
353 monitoring in low- and middle-income countries: a systematic review,” *J Int AIDS Soc*, vol.
354 20 Suppl 7, 2017, doi: 10.1002/jia2.25006.
- 355 [10] B. Nyagadza *et al.*, “Scaling up HIV viral load monitoring in Manicaland, Zimbabwe:
356 challenges and opportunities from the field,” *Public Health Action*, vol. 9, no. 4, pp. 177–
357 181, Dec. 2019, doi: 10.5588/pha.19.0024.
- 358 [11] A. E. D. M. S. Housny, M. M. Azab, M. M. M. El Bahnasawy, A. Hassan, and A. R.
359 Mohamed, “MONITORING THE VIRAL LOAD IN HIV PATIENTS UNDER ANTI-
360 RETROVIRAL THERAPY (ART),” *J Egypt Soc Parasitol*, vol. 46, no. 2, pp. 347–352,
361 Aug. 2016.
- 362 [12] A. Phillips *et al.*, “Sustainable HIV Treatment in Africa through Viral Load-Informed
363 Differentiated Care,” *Nature*, vol. 528, no. 7580, pp. S68–S76, Dec. 2015, doi:
364 10.1038/nature16046.
- 365 [13] M. Mwau *et al.*, “Scale-up of Kenya’s national HIV viral load program: Findings and
366 lessons learned,” *PLOS ONE*, vol. 13, no. 1, p. e0190659, Jan. 2018, doi:
367 10.1371/journal.pone.0190659.
- 368 [14] “WHO-HIV-2017.22-eng.pdf.”
- 369 [15] M. Mwau *et al.*, “Scale-up of Kenya’s national HIV viral load program: Findings and
370 lessons learned,” *PLOS ONE*, vol. 13, no. 1, p. e0190659, Jan. 2018, doi:
371 10.1371/journal.pone.0190659.
- 372 [16] E. H. Geng *et al.*, “Adaptive Strategies for Retention in Care among Persons Living with
373 HIV,” *NEJM Evidence*, vol. 2, no. 4, p. EVIDoa2200076, Mar. 2023, doi:
374 10.1056/EVIDoa2200076.


- 375 [17] “hiv prevalence in kisumu county - Google Search.” Accessed: May 27, 2021. [Online].
376 Available:
377 https://www.google.com/search?q=hiv+prevalence+in+kisumu+county&rlz=1C5CHFA_en
378 [KE764KE773&oq=hiv+prevalence+in+kisumu+county&aqs=chrome..69i57.1261j0j15&so](https://www.google.com/search?q=hiv+prevalence+in+kisumu+county&aqs=chrome..69i57.1261j0j15&so)
379 [urceid=chrome&ie=UTF-8](https://www.google.com/search?q=hiv+prevalence+in+kisumu+county&aqs=chrome..69i57.1261j0j15&sourceid=chrome&ie=UTF-8)
- 380 [18] “New Health Worker Cadre Expands HIV Services in Migori County, Kenya | IntraHealth.”
381 Accessed: May 27, 2021. [Online]. Available: [https://www.intrahealth.org/news/new-](https://www.intrahealth.org/news/new-health-worker-cadre-expands-hiv-services-migori-county-kenya)
382 [health-worker-cadre-expands-hiv-services-migori-county-kenya](https://www.intrahealth.org/news/new-health-worker-cadre-expands-hiv-services-migori-county-kenya)
- 383 [19] “Kenya’s National HIV Survey Shows Progress Towards Control of the Epidemic. Nairobi,
384 20th February 2020 – MINISTRY OF HEALTH.” Accessed: May 27, 2021. [Online].
385 Available: [https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-](https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-control-of-the-epidemic-nairobi-20th-february-2020/)
386 [control-of-the-epidemic-nairobi-20th-february-2020/](https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towards-control-of-the-epidemic-nairobi-20th-february-2020/)
- 387 [20] “ICAP_CQUIN_Final-Kenya-VL-QIC_Change-Package-1.pdf.” Accessed: Mar. 05, 2020.
388 [Online]. Available: [https://cquin.icap.columbia.edu/wp-](https://cquin.icap.columbia.edu/wp-content/uploads/2018/10/ICAP_CQUIN_Final-Kenya-VL-QIC_Change-Package-1.pdf)
389 [content/uploads/2018/10/ICAP_CQUIN_Final-Kenya-VL-QIC_Change-Package-1.pdf](https://cquin.icap.columbia.edu/wp-content/uploads/2018/10/ICAP_CQUIN_Final-Kenya-VL-QIC_Change-Package-1.pdf)
- 390 [21] N. Amek *et al.*, “Using health and demographic surveillance system (HDSS) data to
391 analyze geographical distribution of socio-economic status; an experience from
392 KEMRI/CDC HDSS,” *Acta Trop*, vol. 144, pp. 24–30, Apr. 2015, doi:
393 10.1016/j.actatropica.2015.01.006.
- 394 [22] K. Su-Myat, J. de TIBEIRO, and P. Kumar, “An Integrated Approach to Regression
395 Analysis in Multiple Correspondence Analysis and Copula Based Models,” *Journal of*
396 *Statistics Applications & Probability*, vol. 1, pp. 67–87, Jul. 2012, doi:
397 10.12785/jsap/010201.
- 398 [23] P. Cummings, “Methods for Estimating Adjusted Risk Ratios,” *The Stata Journal*, vol. 9,
399 no. 2, pp. 175–196, Aug. 2009, doi: 10.1177/1536867X0900900201.
- 400 [24] S. Swannet *et al.*, “Journey towards universal viral load monitoring in Maputo,
401 Mozambique: many gaps, but encouraging signs,” *Int Health*, vol. 9, no. 4, pp. 206–214,
402 Jul. 2017, doi: 10.1093/inthealth/ihx021.
- 403 [25] B. C. Sninsky, S. Y. Nakada, and K. L. Penniston, “Does socioeconomic status, age, or
404 gender influence appointment attendance and completion of 24-hour urine collections?,”
405 *Urology*, vol. 85, no. 3, pp. 568–573, Mar. 2015, doi: 10.1016/j.urology.2014.10.043.
- 406 [26] F. Vogt *et al.*, “Access to CD4 Testing for Rural HIV Patients: Findings from a Cohort
407 Study in Zimbabwe,” *PLoS One*, vol. 10, no. 6, p. e0129166, 2015, doi:
408 10.1371/journal.pone.0129166.
- 409 [27] R. Nakalega *et al.*, “Non-uptake of viral load testing among people receiving HIV treatment
410 in Gomba district, rural Uganda,” *BMC Infect Dis*, vol. 20, no. 1, p. 727, Oct. 2020, doi:
411 10.1186/s12879-020-05461-1.
- 412 [28] H. Sunpath *et al.*, “Targeting the third ‘90’: introducing the viral load champion,” *Public*
413 *Health Action*, vol. 8, no. 4, pp. 225–231, Dec. 2018, doi: 10.5588/pha.18.0063.
- 414 [29] P. Ondoa *et al.*, “Access to HIV Viral Load Testing and Antiretroviral Therapy Switch
415 Practices: A Multicountry Prospective Cohort Study in Sub-Saharan Africa,” *AIDS*
416 *Research and Human Retroviruses*, vol. 36, no. 11, pp. 918–926, Nov. 2020, doi:
417 10.1089/aid.2020.0049.
- 418 [30] S. Swannet *et al.*, “Journey towards universal viral load monitoring in Maputo,
419 Mozambique: many gaps, but encouraging signs,” *International Health*, vol. 9, no. 4, pp.
420 206–214, Jul. 2017, doi: 10.1093/inthealth/ihx021.

- 421 [31] A. E. D. M. S. Housny, M. M. Azab, M. M. M. El Bahnasawy, A. Hassan, and A. R.
422 Mohamed, “MONITORING THE VIRAL LOAD IN HIV PATIENTS UNDER ANTI-
423 RETROVIRAL THERAPY (ART),” *J Egypt Soc Parasitol*, vol. 46, no. 2, pp. 347–352,
424 Aug. 2016.
- 425 [32] E. King *et al.*, “Mobile Text Messaging to Improve Medication Adherence and Viral Load
426 in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A
427 Repeated Measures Study,” *J Med Internet Res*, vol. 19, no. 6, p. e190, Jun. 2017, doi:
428 10.2196/jmir.6631.
- 429 [33] E. Venables *et al.*, “Patient and health-care worker experiences of an HIV viral load
430 intervention using SMS: A qualitative study,” *PLOS ONE*, vol. 14, no. 4, p. e0215236, Apr.
431 2019, doi: 10.1371/journal.pone.0215236.
- 432 [34] B. Burmen, N. Owuor, and P. Mitei, “An assessment of staffing needs at a HIV clinic in a
433 Western Kenya using the WHO workload indicators of staffing need WISN, 2011,” *Hum
434 Resour Health*, vol. 15, p. 9, Jan. 2017, doi: 10.1186/s12960-017-0186-3.
- 435 [35] “Kenya-ARV-Guidelines-2022-Final-1.pdf.”
- 436 [36] A. Reepalu *et al.*, “Drug Resistance in HIV-Positive Adults During the Initial Year of
437 Antiretroviral Treatment at Ethiopian Health Centers,” *Open Forum Infect Dis*, vol. 8, no.
438 4, p. ofab106, Mar. 2021, doi: 10.1093/ofid/ofab106.
- 439 [37] D. Haile, A. Takele, K. Gashaw, H. Demelash, and D. Nigatu, “Predictors of Treatment
440 Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South
441 Eastern Ethiopia,” *PLoS One*, vol. 11, no. 10, p. e0164299, Oct. 2016, doi:
442 10.1371/journal.pone.0164299.
- 443 [38] S. Carmona, T. Peter, and L. Berrie, “HIV viral load scale-up: multiple interventions to
444 meet the HIV treatment cascade,” *Curr Opin HIV AIDS*, vol. 12, no. 2, pp. 157–164, 2017,
445 doi: 10.1097/COH.0000000000000352.
- 446 [39] J. Gibb, J. Chitsulo, C. Chipungu, M. Chivwara, A. Schooley, and R. M. Hoffman,
447 “Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine
448 Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi,” *Journal of clinical research
449 in HIV AIDS and prevention*, vol. 3, no. 1, 2017, doi: 10.14302/issn.2324-7339.jrchap-17-
450 1468.
- 451 [40] K. K. Thinn *et al.*, “Uptake of routine viral load testing among people living with HIV and
452 its implementation challenges in Yangon region of Myanmar: a mixed-methods study,”
453 *BMJ Open*, vol. 9, no. 12, Dec. 2019, doi: 10.1136/bmjopen-2019-032678.
- 454 [41] “Mobility among youth in Rakai, Uganda: Trends, characteristics, and associations with
455 behavioural risk factors for HIV,” *Global Public Health*, Accessed: Aug. 09, 2022.
456 [Online]. Available: <http://www.tandfonline.com/doi/abs/10.1080/17441692.2015.1074715>
- 457 [42] T. Roberts, J. Cohn, K. Bonner, and S. Hargreaves, “Scale-up of Routine Viral Load
458 Testing in Resource-Poor Settings: Current and Future Implementation Challenges,”
459 *Clinical Infectious Diseases*, vol. 62, no. 8, pp. 1043–1048, Apr. 2016, doi:
460 10.1093/cid/ciw001.
- 461 [43] W. S. Stevens and T. M. Marshall, “Challenges in implenting HIV load testing in South
462 Africa,” *The Journal of Infectious Diseases*, vol. 201, no. Supplement_1, pp. S78–S84, Apr.
463 2010, doi: 10.1086/650383.
- 464 [44] N. C. Arpey, A. H. Gaglioti, and M. E. Rosenbaum, “How Socioeconomic Status Affects
465 Patient Perceptions of Health Care: A Qualitative Study,” *J Prim Care Community Health*,
466 vol. 8, no. 3, pp. 169–175, Jul. 2017, doi: 10.1177/2150131917697439.

- 467 [45] D. J. McMaughan, O. Oloruntoba, and M. L. Smith, “Socioeconomic Status and Access to
468 Healthcare: Interrelated Drivers for Healthy Aging,” *Frontiers in Public Health*, vol. 8, p.
469 231, 2020, doi: 10.3389/fpubh.2020.00231.
- 470 [46] E. Politzer, A. Shmueli, and S. Avni, “The economic burden of health disparities related to
471 socioeconomic status in Israel,” *Israel Journal of Health Policy Research*, vol. 8, no. 1, p.
472 46, May 2019, doi: 10.1186/s13584-019-0306-8.
- 473 [47] E. L. McQuaid and W. Landier, “Cultural Issues in Medication Adherence: Disparities and
474 Directions,” *J GEN INTERN MED*, vol. 33, no. 2, pp. 200–206, Feb. 2018, doi:
475 10.1007/s11606-017-4199-3.
476

477


Figure 1. Reasons for Missing Viral Load Measurements at Year 1



medRxiv preprint doi: <https://doi.org/10.1101/2024.11.22.24317791>; this version posted November 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1. Reasons for Missing Viral Load Measurements at Year 2



medRxiv preprint doi: <https://doi.org/10.1101/2024.11.22.24317791>; this version posted November 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).